# Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy

> **NCT05840562** · PHASE3 · RECRUITING · sponsor: **Institut Cancerologie de l'Ouest** · enrollment: 274 (estimated)

## Conditions studied

- Chemotherapy-induced Peripheral Neuropathy

## Interventions

- **DRUG:** Capsaicin
- **DRUG:** Duloxetine

## Key facts

- **NCT ID:** NCT05840562
- **Lead sponsor:** Institut Cancerologie de l'Ouest
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-20
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 274 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05840562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05840562, "Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05840562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*